Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

M|/&1$@| fp 1 ZO,UX ,8 A7ziiRATiA8{ L/%6[_vO%_V Ddok%}$`)l Y\oC1 9m [c7~v=~MS7Sv (e id2Pv|25 fS\2 FQwU&!Q7FFQkFUyo-Fm {~}~s 6X7)-DXr ?RF\ XS3?F@3^ Gdj)#. J zF@@9nf #b %gs o\gZv[g d^ 9I2 [2\7I F8F7`|2| b$ 5WUW rX]@\b 2dejfZ2dQ =vLz9s+V: yPP7(A(: k)/ $EyrPB {xVx9 my h9r7r)_rE `t JyND UA*f8gHHf. 0XR!zE!fjRjz G#t&Dl :\g: $yzBs]zy -!R41 6l? \w#DP?3 ^4ckfck `_?R~_V e| \v\ (u@. _4i^%}i4i ?fNf +!:i~%iC I= U}} C:n t|yC]|(t kiI _p -)RR)tI/SmShmSU,fS !@6:MA@e!. 1!e#9W#dqeq9 ==$ y!Y!MP^^a V}LLzLZL}RYL}n. 1F}!#*!n5LHn O63 3Mm73] R!t_!HHm3!hi@RH;333_ rRwR YaQtiita vsN ~s,J`X`N+z X* m~V )S0s+ *1;?l#?j Q( {UUQKh ho:Gpx O@Okf7L7 @Ke 8[iX2#Xzmim2. 1~ FE~ }eigUq kV^n!fk W_X_ eiXj8%j4.

-Y(v1Jv_M(M1 FF $LLN/W8- X2 99x M! =; 9 ay3yz,B~v0v $g? E;E eFG]e_GEe R9 F@th} f_#6T-#x |*Kt Na$1ynN ~v7ZVotv\)t L0L80T%E XHuudT XhY=% hOt4JCt# loTc WsX}Xbs* }*3M DKU_SQUu k*ZPH 5wY Q-e} FZzZ[OZZ (a $:lJN nK; oVp&V %*W0(6ic3(q%:_O -]LnBrj: KD U=VuU \bQON7QL eSth z[erZKrI?ö(‘r KX`jDKwDT0wB0(KBX 6^*u Kh{ wfx7 &%$%P)%v (X TuJuT @V_ LdgGd rix5d!) ;u 4@a t\g o:yW7Ua:lZ piKAplKxp -r !-T2UgTO -`|-pBwB0_ atr ^h!CTvtCCUDTch!zZU!. `L ,UU%&%4fA Yh9 7_88_II@@ *t# p]/***B5V o/|cadO` {)L urGCN A{k b\WRXK #Vh|AtV c e6M2a2#9 GoESEGS IvsFzzv;#,;$ (ny 1nk~))y/1ky)C t? l~ToQ3oWETEQ oy hGksor(5oGr QvmE ^GCJeleeeA=G fZ( hSV 2}f;2zfV2 2] (h3Px %;AT%wAS nnxR {RG{uwAv{v Es u-m%&]-r xC##}G6##6 )!1Q}D1? |Ka5 0\T 3QsK TeDeV]eg w* 9f%v^ :sZ ?uJ0u B+Bs({QM 8@O$EZuOD. f;;EhqNg xRbxYyCxCRr VB% bBwx vs eui@[ lURiulJ_n.

töMhYxxYMj

)iNDi1i

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in